QuantRx Biomedical Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Shalom Hirschman
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 13.3yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$261k |
| Jun 30 2022 | n/a | n/a | -US$262k |
| Mar 31 2022 | n/a | n/a | -US$259k |
| Dec 31 2021 | n/a | n/a | -US$260k |
| Sep 30 2021 | n/a | n/a | -US$263k |
| Jun 30 2021 | n/a | n/a | -US$265k |
| Mar 31 2021 | n/a | n/a | -US$267k |
| Dec 31 2020 | US$4k | US$4k | -US$253k |
| Sep 30 2020 | n/a | n/a | -US$502k |
| Jun 30 2020 | n/a | n/a | -US$536k |
| Mar 31 2020 | n/a | n/a | -US$554k |
| Dec 31 2019 | US$42k | US$42k | -US$622k |
| Sep 30 2019 | n/a | n/a | -US$822k |
| Jun 30 2019 | n/a | n/a | -US$699k |
| Mar 31 2019 | n/a | n/a | -US$744k |
| Dec 31 2018 | US$31k | US$31k | -US$737k |
Compensation vs Market: Insufficient data to establish whether Shalom's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Shalom's compensation with company performance.
CEO
Shalom Hirschman (87 yo)
13.3yrs
Tenure
Dr. Shalom Z. Hirschman, M.D serves as Co-founder of ImmunoCellular Therapeutics, Ltd., and its Chief Scientific Officer since December 1, 2021. Dr. Hirschman has been the Chairman at QuantRX Biomedical Co...